Bioworld Technology CO., Ltd.



FXR2 (E576) Peptide

Cat No.: BS2008P

Background

Fragile X syndrome is the most frequent form of inherited mental retardation and is the result of transcriptional silencing of the FMR1 gene on the X chromosome. The FMR1 gene contains a distinct CpG dinucleotide repeat located in the 5' untranslated region of the gene, and in the fragile X syndrome this tandem repeat is substantially amplified and subjected to extensive methylation and enhanced transcriptional silencing. The FMR1 protein (or FMRP) is an RNA-binding protein that associates with polyribosomes and is a likely component of a messenger ribonuclear protein (mRNP) particle. It contains several features that are characteristics of RNA-binding proteins, including two hnRNPK homology (KH) domains and an RGG amino acid motif (RGG box). FMR1 can also interact with two fragile X syndrome related factors, FXR1 and FXR2, and these proteins form heterodimers through their N-terminal coilcoiled domains. FMR1 localizes to both the nucleus and the cytoplasm, and since it contains both a nuclear localization signal and a nuclear export signal it is also implicated in the nucleo-cytoplasmic transport of mRNAs.

Swiss-Prot

P51116

Applications

Blocking

Specificity

This peptide can be used with studies using BS2008 FXR2 (E576) pAb.

Purification & Purity

Synthetic peptide FXR2 (E576). (Note: the amino acid sequence is proprietary). The purity is > 98%.

Product

1 mg/ml in DI water.

Storage & Stability

Store at 4 ${\rm C}$ short term. Aliquot and store at -20 ${\rm C}$ long term. Avoid freeze-thaw cycles.

Research Use

For research use only, not for use in diagnostic procedure.